HDAC6 and neoplasm: The combination of the HDAC6 inhibitor nexturastat and an anti-PD-1 antibody induced anti-tumor immune responses in syngeneic melanoma tumor models by increasing the infiltration of immune cells, increasing central and effector T cell memory, and decreasing pro-tumorigenic M2 macrophages [98].